Switch theme
Sign up to access all valuation multiples
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
2018
78
LTM Revenue $48K
LTM EBITDA n/a
-$129M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Acrivon Therapeutics has a last 12-month revenue of $48K and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Acrivon Therapeutics achieved revenue of n/a and an EBITDA of -$88.2M.
Acrivon Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Acrivon Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$66.6M | -$88.2M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$31.2M | -$60.4M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Acrivon Therapeutics's stock price is $2.
Acrivon Therapeutics has current market cap of $47.0M, and EV of -$129M.
See Acrivon Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$129M | $47.0M | XXX | XXX | XXX | XXX | $-2.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Acrivon Therapeutics has market cap of $47.0M and EV of -$129M.
Acrivon Therapeutics's trades at -2692.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Acrivon Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Acrivon Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$129M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 1.5x | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAcrivon Therapeutics's NTM/LTM revenue growth is 1672%
Acrivon Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Acrivon Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Acrivon Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Acrivon Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acrivon Therapeutics acquired XXX companies to date.
Last acquisition by Acrivon Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Acrivon Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Acrivon Therapeutics founded? | Acrivon Therapeutics was founded in 2018. |
| Where is Acrivon Therapeutics headquartered? | Acrivon Therapeutics is headquartered in United States of America. |
| How many employees does Acrivon Therapeutics have? | As of today, Acrivon Therapeutics has 78 employees. |
| Who is the CEO of Acrivon Therapeutics? | Acrivon Therapeutics's CEO is Mr. Peter Blume-Jensen, M.D.,PhD. |
| Is Acrivon Therapeutics publicy listed? | Yes, Acrivon Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Acrivon Therapeutics? | Acrivon Therapeutics trades under ACRV ticker. |
| When did Acrivon Therapeutics go public? | Acrivon Therapeutics went public in 2022. |
| Who are competitors of Acrivon Therapeutics? | Similar companies to Acrivon Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Acrivon Therapeutics? | Acrivon Therapeutics's current market cap is $47.0M |
| What is the current revenue of Acrivon Therapeutics? | Acrivon Therapeutics's last 12-month revenue is $48K. |
| What is the current EV/Revenue multiple of Acrivon Therapeutics? | Current revenue multiple of Acrivon Therapeutics is -2692.7x. |
| Is Acrivon Therapeutics profitable? | Yes, Acrivon Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
